Literature DB >> 25548231

Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.

Jeremy D Waight1, Shinji Takai2, Bo Marelli1, Guozhong Qin1, Kenneth W Hance1, Dong Zhang1, Robert Tighe1, Yan Lan1, Kin-Ming Lo1, Helen Sabzevari1, Robert Hofmeister3, Nicholas S Wilson4.   

Abstract

CD4(+) regulatory T cells (Tregs) are critical for maintaining self-tolerance and function to prevent autoimmune disease. High densities of intratumoral Tregs are generally associated with poor patient prognosis, a correlation attributed to their broad immune-suppressive features. Two major populations of Tregs have been defined, thymically derived natural Tregs (nTregs) and peripherally induced Tregs (iTregs). However, the relative contribution of nTregs versus iTregs to the intratumoral Treg compartment remains controversial. Demarcating the proportion of nTregs versus iTregs has important implications in the design of therapeutic strategies to overcome their antagonistic effects on antitumor immune responses. We used epigenetic, phenotypic, and functional parameters to evaluate the composition of nTregs versus iTregs isolated from mouse tumor models and primary human tumors. Our findings failed to find evidence for extensive intratumoral iTreg induction. Rather, we identified a population of Foxp3-stable nTregs in tumors from mice and humans.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25548231      PMCID: PMC4298129          DOI: 10.4049/jimmunol.1402725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.

Authors:  Gang Zhou; Hyam I Levitsky
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta.

Authors:  Ramesh K Selvaraj; Terrence L Geiger
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

3.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Authors:  L Gorelik; R A Flavell
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

4.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma.

Authors:  Y Hasegawa; S Takanashi; Y Kanehira; T Tsushima; T Imai; K Okumura
Journal:  Cancer       Date:  2001-03-01       Impact factor: 6.860

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  A central role for induced regulatory T cells in tolerance induction in experimental colitis.

Authors:  Dipica Haribhai; Wen Lin; Brandon Edwards; Jennifer Ziegelbauer; Nita H Salzman; Marc R Carlson; Shun-Hwa Li; Pippa M Simpson; Talal A Chatila; Calvin B Williams
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

7.  Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.

Authors:  Louise A Koopman Van Aarsen; Diane R Leone; Steffan Ho; Brian M Dolinski; Patricia E McCoon; Doreen J LePage; Rebecca Kelly; Glenna Heaney; Paul Rayhorn; Carl Reid; Kenneth J Simon; Gerald S Horan; Nianjun Tao; Humphrey A Gardner; Marilyn M Skelly; Allen M Gown; Gareth J Thomas; Paul H Weinreb; Stephen E Fawell; Shelia M Violette
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

8.  Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation.

Authors:  Hiromasa Morikawa; Naganari Ohkura; Alexis Vandenbon; Masayoshi Itoh; Sayaka Nagao-Sato; Hideya Kawaji; Timo Lassmann; Piero Carninci; Yoshihide Hayashizaki; Alistair R R Forrest; Daron M Standley; Hiroshi Date; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-27       Impact factor: 11.205

9.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

10.  T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.

Authors:  Linda Fahlén; Simon Read; Leonid Gorelik; Stephen D Hurst; Robert L Coffman; Richard A Flavell; Fiona Powrie
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  29 in total

1.  Lactobacillus casei regulates differentiation of Th17/Treg cells to reduce intestinal inflammation in mice.

Authors:  Kai Wang; Hao Dong; Yu Qi; Zhihua Pei; Shushuai Yi; Xiaojie Yang; Yanli Zhao; Fanxing Meng; Shouping Yu; Tiezhong Zhou; Guixue Hu
Journal:  Can J Vet Res       Date:  2017-04       Impact factor: 1.310

2.  ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.

Authors:  Huanling Zhang; Yanyan Li; Xiaoping Liu; Zhaoduan Liang; Mengyong Yan; Qiang Liu; Anan Chen; Yifeng Bao; Chengzhi Zhou; Shiyue Li; Cassian Yee; Yi Li
Journal:  Immunology       Date:  2018-06-14       Impact factor: 7.397

Review 3.  Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Authors:  Abigail E Overacre-Delgoffe; Dario A A Vignali
Journal:  Cancer Immunol Res       Date:  2018-08       Impact factor: 11.151

Review 4.  Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Authors:  Theodore S Johnson; Tracy Mcgaha; David H Munn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 5.  Tumor-infiltrating regulatory T cells: origins and features.

Authors:  Guoping Deng
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05

Review 6.  Metabolic profiles of regulatory T cells in the tumour microenvironment.

Authors:  Disha Rao; Fabienne Verburg; Kathrin Renner; Daniel S Peeper; Ruben Lacroix; Christian U Blank
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

Review 7.  Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.

Authors:  Hiroshi Yano; Lawrence P Andrews; Creg J Workman; Dario A A Vignali
Journal:  Immunology       Date:  2019-06-03       Impact factor: 7.397

8.  Regulatory and T Effector Cells Have Overlapping Low to High Ranges in TCR Affinities for Self during Demyelinating Disease.

Authors:  Jennifer D Hood; Veronika I Zarnitsyna; Cheng Zhu; Brian D Evavold
Journal:  J Immunol       Date:  2015-09-18       Impact factor: 5.422

9.  Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.

Authors:  Eleonora Timperi; Ilenia Pacella; Valeria Schinzari; Chiara Focaccetti; Luca Sacco; Francesco Farelli; Roberto Caronna; Gabriella Del Bene; Flavia Longo; Antonio Ciardi; Sergio Morelli; Anna Rita Vestri; Piero Chirletti; Vincenzo Barnaba; Silvia Piconese
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 10.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.